Clinical design and competition issues

Clinical design and competition issues

On the heels of a negative review by FDA's Peripheral and Central Nervous System Drugs Advisory Committee, Cephalon Inc. faces the decision whether to conduct an additional trial of Myotrophin IGF-1 to confirm the positive results of its North American trial in amyotrophic lateral sclerosis.

The company last week said it can't justify the expense of another trial prior to marketing approval, although it has been planning a combination study with Rhone-Poulenc Rorer's Rilutek riluzole, which is the only drug approved for ALS. Whether or not CEPH does

Read the full 926 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE